{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:00:16Z","timestamp":1790420416442,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U01DK108328"],"award-info":[{"award-number":["U01DK108328"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>The premise of personalized medicine is that patients exhibit significant heterogeneity and respond differently to treatments. The best treatment for one patient may not be suitable for another. In this paper, we propose a Bayesian adaptive design for an avatar-driven clinical trial, using mouse or laboratory animal grafts to create personalized tumor models that guide individualized patient treatment while accounting for translational discrepancy between avatars and patients. We jointly model the tumor growth of avatars and the clinical outcomes of patients, including toxicity and progression-free survival, to capture the interplay between avatars and their source patients. This joint model enables us to leverage both avatar treatment responses and patient data to predict the treatment utility for each patient and inform the selection of personalized optimal treatments, thereby serving as a digital twin of the patient. To address the fact that avatars may only serve as valid surrogates for treatment effects in a subset of patients, we incorporate a latent-class model that accounts for this translational discrepancy. Through simulation studies, we demonstrate that the proposed design outperforms conventional clinical trials lacking avatar information. Under this design, patients are significantly more likely to receive personalized optimal treatments, leading to improved treatment outcomes.<\/jats:p>","DOI":"10.1093\/biomtc\/ujag165","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T11:20:54Z","timestamp":1789384854000},"source":"Crossref","is-referenced-by-count":0,"title":["A Bayesian adaptive digital twin design for avatar-driven cancer clinical trials"],"prefix":"10.1093","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0630-9506","authenticated-orcid":false,"given":"Peng","family":"Yang","sequence":"first","affiliation":[{"name":"Department of Statistics, Rice University , Houston, TX 77005 ,","place":["United States"]},{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-3407","authenticated-orcid":false,"given":"Yeonhee","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Statistics, Sungkyunkwan University , Jongno-gu, Seoul 03063 ,","place":["Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-2646","authenticated-orcid":false,"given":"Suyu","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, TX 77030 ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"2026092606032786500_bib1","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1517\/17425255.2012.693480","article-title":"Mathematical modeling of tumor growth and tumor growth inhibition in oncology drug development","volume":"8","author":"Bernard","year":"2012","journal-title":"Expert Opinion on Drug Metabolism & Toxicology"},{"key":"2026092606032786500_bib2","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1038\/ng.3967","article-title":"Patient-derived xenografts undergo mouse-specific tumor evolution","volume":"49","author":"Ben-David","year":"2017","journal-title":"Nature Genetics"},{"key":"2026092606032786500_bib3","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.ccell.2022.09.017","article-title":"A path to translation: How 3D patient tumor avatars enable next generation precision oncology","volume":"40","author":"Bose","year":"2022","journal-title":"Cancer Cell"},{"key":"2026092606032786500_bib4","first-page":"73","article-title":"Handling sparsity via the horseshoe","volume-title":"Artificial Intelligence and Statistics","author":"Carvalho","year":"2009"},{"key":"2026092606032786500_bib5","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1093\/biomet\/asq017","article-title":"The horseshoe estimator for sparse signals","volume":"97","author":"Carvalho","year":"2010","journal-title":"Biometrika"},{"key":"2026092606032786500_bib6","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1200\/JCO.2008.21.0807","article-title":"Model-based prediction of phase III overall survival in colorectal cancer on the basis of phase II tumor dynamics","volume":"27","author":"Claret","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"2026092606032786500_bib7","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00280-010-1449-z","article-title":"Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer","volume":"66","author":"Claret","year":"2010","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"2026092606032786500_bib8","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1541-0420.2008.01166.x","article-title":"Bayesian nonparametric nonproportional hazards survival modeling","volume":"65","author":"De\u00a0Iorio","year":"2009","journal-title":"Biometrics"},{"key":"2026092606032786500_bib9","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1158\/0008-5472.CAN-19-3101","article-title":"Systematic establishment of robustness and standards in patient-derived xenograft experiments and analysis","volume":"80","author":"Evrard","year":"2020","journal-title":"Cancer Research"},{"key":"2026092606032786500_bib10","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","article-title":"Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials","volume":"20","author":"Fert\u00e9","year":"2014","journal-title":"Clinical Cancer Research"},{"key":"2026092606032786500_bib11","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nature Medicine"},{"key":"2026092606032786500_bib12","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1158\/1078-0432.CCR-11-0341","article-title":"Tumor engraftment in nude mice and enrichment in stroma-related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer","volume":"17","author":"Garrido-Laguna","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"2026092606032786500_bib13","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1073\/pnas.94.10.5302","article-title":"Acute leukemia with promyelocytic features in PML\/RAR$\\alpha$ transgenic mice","volume":"94","author":"He","year":"1997","journal-title":"Proceedings of the National Academy of Sciences"},{"key":"2026092606032786500_bib14","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1158\/1535-7163.MCT-11-0233","article-title":"A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer","volume":"10","author":"Hidalgo","year":"2011","journal-title":"Molecular Cancer Therapeutics"},{"key":"2026092606032786500_bib15","doi-asserted-by":"crossref","first-page":"48692","DOI":"10.18632\/oncotarget.8961","article-title":"Mantle cell lymphoma in the era of precision medicine: Diagnosis, biomarkers and therapeutic agents","volume":"7","author":"Inamdar","year":"2016","journal-title":"Oncotarget"},{"key":"2026092606032786500_bib16","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1214\/009053604000001147","article-title":"Spike and slab variable selection: frequentist and Bayesian strategies","volume":"33","author":"Ishwaran","year":"2005","journal-title":"The Annals of Statistics"},{"key":"2026092606032786500_bib17","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1093\/annonc\/mdx416","article-title":"Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors","volume":"28","author":"Izumchenko","year":"2017","journal-title":"Annals of Oncology"},{"key":"2026092606032786500_bib18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1158\/1078-0432.CCR-10-2224","article-title":"The ability to form primary tumor xenografts is predictive of increased risk of disease recurrence in early-stage non\u2013small cell lung cancer","volume":"17","author":"John","year":"2011","journal-title":"Clinical Cancer Research"},{"key":"2026092606032786500_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/s41746-024-01073-0","article-title":"Digital twins for health: A scoping review","volume":"7","author":"Katsoulakis","year":"2024","journal-title":"NPJ Digital Medicine"},{"key":"2026092606032786500_bib20","doi-asserted-by":"crossref","first-page":"e1082","DOI":"10.1634\/theoncologist.2018-0672","article-title":"Value of tumor growth rate (TGR) as an early biomarker predictor of patients\u2019 outcome in neuroendocrine tumors (NET): the GREPONET study","volume":"24","author":"Lamarca","year":"2019","journal-title":"The Oncologist"},{"key":"2026092606032786500_bib21","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41591-022-02178-3","article-title":"Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma","volume":"29","author":"Larrayoz","year":"2023","journal-title":"Nature Medicine"},{"key":"2026092606032786500_bib22","first-page":"1344","article-title":"Cancer-genome study challenges mouse \u201cavatars\u201d","volume":"1098","author":"Ledford","year":"2017","journal-title":"Nature"},{"key":"2026092606032786500_bib23","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1214\/13-AOAS661","article-title":"Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity","volume":"7","author":"Liu","year":"2013","journal-title":"The Annals of Applied Statistics"},{"key":"2026092606032786500_bib24","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.2008.19.6121","article-title":"Outcome of deferred initial therapy in mantle-cell lymphoma","volume":"27","author":"Martin","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"2026092606032786500_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.10.010","article-title":"One mouse, one patient paradigm: New avatars of personalized cancer therapy","volume":"344","author":"Malaney","year":"2014","journal-title":"Cancer Letters"},{"key":"2026092606032786500_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1080\/00031305.1975.10479105","article-title":"Ridge regression in practice","volume":"29","author":"Marquardt","year":"1975","journal-title":"The American Statistician"},{"key":"2026092606032786500_bib27","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1200\/JCO.2011.36.9678","article-title":"Prioritizing phase I treatment options through preclinical testing on personalized tumorgraft","volume":"30","author":"Morelli","year":"2012","journal-title":"Journal of Clinical Oncology"},{"key":"2026092606032786500_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.semcancer.2011.09.008","article-title":"New molecular targets in mantle cell lymphoma","volume":"21","author":"Parekh","year":"2011","journal-title":"Seminars in Cancer Biology"},{"key":"2026092606032786500_bib29","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/107327481201900307","article-title":"Mantle cell lymphoma: A clinically heterogeneous disease in need of tailored approaches","volume":"19","author":"Shah","year":"2012","journal-title":"Cancer Control"},{"key":"2026092606032786500_bib30","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1200\/JCO.1993.11.4.802","article-title":"Intermediate lymphocytic lymphoma: clinical and pathologic features of a recently characterized subtype of non-Hodgkin\u2019s lymphoma","volume":"11","author":"Shivdasani","year":"1993","journal-title":"Journal of Clinical Oncology"},{"key":"2026092606032786500_bib31","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.2517-6161.1996.tb02080.x","article-title":"Regression shrinkage and selection via the lasso","volume":"58","author":"Tibshirani","year":"1996","journal-title":"Journal of the Royal Statistical Society: Series B (Statistical Methodology)"},{"key":"2026092606032786500_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3390\/cancers12030677","article-title":"A model of a zebrafish avatar for co-clinical trials","volume":"12","author":"Usai","year":"2020","journal-title":"Cancers"},{"key":"2026092606032786500_bib33","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1200\/JCO.1996.14.4.1269","article-title":"Mantle-cell lymphoma: A population-based clinical study","volume":"14","author":"Velders","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"2026092606032786500_bib34","doi-asserted-by":"crossref","first-page":"104617","DOI":"10.1016\/j.drudis.2026.104617","article-title":"Digital twins for accelerating drug discovery and development: Opportunities and challenges","volume":"31","author":"Venkatapurapu","year":"2026","journal-title":"Drug Discovery Today"},{"key":"2026092606032786500_bib35","doi-asserted-by":"crossref","first-page":"i7","DOI":"10.1093\/annonc\/mdt042.51","article-title":"Ovarian avatar models predictive of platinum response in ovarian cancer patients","volume":"24","author":"Weroha","year":"2013","journal-title":"Annals of Oncology"},{"key":"2026092606032786500_bib36","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1198\/jasa.2011.ap09476","article-title":"Robust EM continual reassessment method in oncology dose finding","volume":"106","author":"Yuan","year":"2011","journal-title":"Journal of the American Statistical Association"},{"key":"2026092606032786500_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1479-5876-11-168","article-title":"Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: Useful tools for preclinical studies of targeted therapies","volume":"11","author":"Zhang","year":"2013","journal-title":"Journal of Translational Medicine"}],"container-title":["Biometrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/82\/3\/ujag165\/71401594\/ujag165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/biometrics\/article-pdf\/82\/3\/ujag165\/71401594\/ujag165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:03:38Z","timestamp":1790417018000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/biometrics\/article\/doi\/10.1093\/biomtc\/ujag165\/8836498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/biomtc\/ujag165","relation":{},"ISSN":["0006-341X","1541-0420"],"issn-type":[{"value":"0006-341X","type":"print"},{"value":"1541-0420","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,1]]},"article-number":"ujag165"}}